[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Johnstone PA, Peng YP, May BC, Inouye WS, Niemtzow RC: Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys; 2001 Jun 1;50(2):353-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: Eighteen patients with xerostomia refractory to pilocarpine therapy after XRT for head and neck malignancy were offered acupuncture as palliation.
  • Acupuncture was provided to three auricular points and one digital point bilaterally, with electrostimulation used variably.
  • Palliative effect as measured by the XI varied from nil to robust (pre- minus post- therapy values of over 20 points).
  • [MeSH-major] Acupuncture Therapy. Head and Neck Neoplasms / radiotherapy. Miotics / therapeutic use. Pilocarpine / therapeutic use. Radiation Injuries / therapy. Xerostomia / therapy
  • [MeSH-minor] Drug Resistance. Humans. Radiotherapy / adverse effects

  • MedlinePlus Health Information. consumer health - Acupuncture.
  • MedlinePlus Health Information. consumer health - Dry Mouth.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PILOCARPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11380221.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Miotics; 01MI4Q9DI3 / Pilocarpine
  •  go-up   go-down


2. Vilaplana Palomer J: [Incessant atrial tachycardia and a cerebral tumor]. Rev Esp Cardiol; 2003 May;56(5):519-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Taquicardia auricular incesante y tumoración cerebral.
  • We report the case of an asymptomatic 78-year-old woman in whom incessant atrial tachycardia refractory to many pharmacological treatments appeared.
  • Treatment of the tumor resolved the rhythm disorder.
  • [MeSH-major] Brain Neoplasms / complications. Cysts / complications. Tachycardia, Ectopic Atrial / etiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12737792.001).
  • [ISSN] 0300-8932
  • [Journal-full-title] Revista española de cardiología
  • [ISO-abbreviation] Rev Esp Cardiol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


3. Adriane K, Huang J, Ding G, Chen J, Liu Y: Self assembled magnetic PVP/PVA hydrogel microspheres; magnetic drug targeting of VX2 auricular tumours using pingyangmycin. J Drug Target; 2006 May;14(4):243-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Self assembled magnetic PVP/PVA hydrogel microspheres; magnetic drug targeting of VX2 auricular tumours using pingyangmycin.
  • Chemotherapy in cancer treatment is associated with serious side effects and as a result there is great interest in research aimed at bringing down the level of systemic cytotoxicity.
  • With advances in material science, magnetic drug targeting has emerged as one of the viable ways of attaining this.
  • In this study, we used self assembled PVP/PVA magnetic hydrogel microspheres to deliver pingyangmycin (Bleomycin A5) to rabbit auricular VX2 tumours in the presence of a 0.5 T permanent magnet both during and 24 h after perfusion.
  • In group D (1 mg pingyangmycin in 50 mg ferrofluid without a magnet) 2 weeks post treatment, there was statistically significant difference compared to the control (p = 0.05) in favor of group D.
  • However, when compared to the group with 1 mg pingyangmycin(BLM) in 50 mg of ferrofluid and 0.5 mg (BLM) in 50 mg ferrofluid both with a permanent magnet in place for 24 h, the statistically significant difference was in favor of combined treatment, i.e. ferrofluid carrying drug in presence of a permanent magnet (p = 0.01).
  • The microspheres in conjunction with the magnet did deliver pingyangmycin to the tumour and hence may be of use in future as far as magnetic drug targeting is concerned.
  • However, more studies are still required to establish biodistribution and biostability not to forget drug release of ferrofluid of different chemotherapeutic agents available.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bleomycin / analogs & derivatives. Drug Delivery Systems. Ear Neoplasms / drug therapy. Hydrogel / administration & dosage. Magnetics. Microspheres
  • [MeSH-minor] Animals. Drug Carriers. Polyvinyl Alcohol. Povidone. Rabbits

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. POLYVINYL ALCOHOL .
  • Hazardous Substances Data Bank. POLYVINYLPYRROLIDONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16777683.001).
  • [ISSN] 1061-186X
  • [Journal-full-title] Journal of drug targeting
  • [ISO-abbreviation] J Drug Target
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 11056-06-7 / Bleomycin; 11116-32-8 / bleomycetin; 25852-47-5 / Hydrogel; 9002-89-5 / Polyvinyl Alcohol; 9003-39-8 / Povidone
  •  go-up   go-down


Advertisement
4. Jinbo M, Ueda K, Kaneda Y, Sudo M, Li TS, Hamano K: Video-assisted transcatheter lung perfusion regional chemotherapy. Eur J Cardiothorac Surg; 2005 Jun;27(6):1079-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Video-assisted transcatheter lung perfusion regional chemotherapy.
  • METHODS: Under fluoroscopic and thoracoscopic guidance, five canine left lungs were isolated by means of an endovascular technique comprising pulmonary artery cannulation through the right femoral vein and pulmonary vein cannulation through the left auricular appendage (VATS-ILP).
  • Both VATS-ILP and conventional ILP delivered a high dose of cisplatin to the treated lung (total platinum concentration: 48+/-17 microg/g tissue for VATS-ILP vs. 51+/-19 microg/g tissue for conventional ILP, P>0.1) without significant systemic leakage (total platinum concentration: 0.4+/-0.1 microg/ml plasma vs. 0.5+/-0.2 microg/ml plasma, P>0.1).
  • A clinical trial of VATS-ILP with cytotoxic drugs is warranted.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Cisplatin / administration & dosage. Lung. Lung Neoplasms / drug therapy. Thoracic Surgery, Video-Assisted

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896621.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 3.4.15.1 / Peptidyl-Dipeptidase A; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Elbayoumi TA, Torchilin VP: Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice. Int J Pharm; 2008 Jun 5;357(1-2):272-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice.
  • A mucocutaneous reaction in mice associated with Doxil treatment was identified as auricular erythema (AE).
  • This problem is of general significance, since cutaneous reactions often lead to alterations of Doxil dosing regimen in patients and might subsequently compromise the therapeutic outcome of cancer treatment.
  • Tumor-bearing mice were used to study the biodistribution and skin-tissue accumulation effects of the tumor-targeted Doxil (the clinically used anti-cancer formulation) coupled with the anti-cancer monoclonal 2C5 antibody (mAb 2C5) as well as AE caused by Doxil application.
  • Thus, targeting of Doxil with the anti-cancer mAb 2C5 not only can increase the tumor-specific accumulation of the drug, but also diminishes the cutaneous side effect of the original Doxil therapy.

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Drugs. 2006 Jun;17(5):587-95 [16702817.001]
  • [Cites] Oncology. 2005;69(4):348-53 [16293974.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Oct;33(10):1196-205 [16763815.001]
  • [Cites] J Liposome Res. 2007;17(1):1-14 [17454399.001]
  • [Cites] Eur J Pharm Sci. 2007 Nov;32(3):159-68 [17707615.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3093-100 [10963637.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):1029-33 [11038041.001]
  • [Cites] Arch Dermatol. 2000 Dec;136(12):1475-80 [11115157.001]
  • [Cites] Biochim Biophys Acta. 2001 Apr 2;1511(2):397-411 [11286983.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):464-9 [11520141.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 1;1515(2):144-58 [11718670.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):910-8 [12123337.001]
  • [Cites] Biochim Biophys Acta. 2003 Jan 10;1609(1):102-8 [12507764.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):86-92 [12517782.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Sep;306(3):1058-67 [12808004.001]
  • [Cites] Biochim Biophys Acta. 2004 May 27;1663(1-2):167-77 [15157619.001]
  • [Cites] Expert Opin Ther Targets. 2004 Aug;8(4):335-53 [15268628.001]
  • [Cites] J Control Release. 2004 Nov 5;100(1):135-44 [15491817.001]
  • [Cites] FEBS Lett. 1990 Jul 30;268(1):235-7 [2384160.001]
  • [Cites] Biochim Biophys Acta. 1991 Jul 1;1066(1):29-36 [2065067.001]
  • [Cites] Biochim Biophys Acta. 1991 Sep 30;1068(2):133-41 [1911826.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460-4 [1763060.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1777-85 [7602367.001]
  • [Cites] Immunol Lett. 1995 Jul-Aug;47(1-2):147-9 [8537094.001]
  • [Cites] BMJ. 1997 Aug 16;315(7105):422-5 [9277611.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3185-91 [9336354.001]
  • [Cites] Oncol Res. 1997;9(8):439-46 [9436197.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):711-6 [9739435.001]
  • [Cites] Nat Rev Drug Discov. 2005 Feb;4(2):145-60 [15688077.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6 Suppl 13):196-205 [15717745.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3567-73 [15867261.001]
  • [Cites] Pharm Res. 2005 Jun;22(6):933-9 [15948037.001]
  • [Cites] J Drug Target. 2005 Jul;13(6):337-43 [16278153.001]
  • [Cites] Drug Discov Today. 2006 Sep;11(17-18):812-8 [16935749.001]
  • (PMID = 18329201.001).
  • [ISSN] 0378-5173
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL055519-12; United States / NHLBI NIH HHS / HL / R01 HL055519; United States / NHLBI NIH HHS / HL / R01 HL055519-12; United States / NHLBI NIH HHS / HL / R01 HL55519
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Monoclonal; 0 / Indium Radioisotopes; 0 / Liposomes; 0 / Pharmaceutical Vehicles; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ NIHMS51910; NLM/ PMC2680692
  •  go-up   go-down


6. Asghar AH, Mahmood H, Faheem M, Rizvi S, Khan KA, Irfan J: Porocarcinoma: a rare sweat gland malignancy. J Coll Physicians Surg Pak; 2009 Jun;19(6):389-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment with wide local excision but metastatic lesions can be treated with chemotherapy.
  • Here, we present a case report of 52 years old male who presented with a fungating growth on left pre-auricular region that came out to be a case of ECP on histopathological examination.
  • [MeSH-minor] Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Middle Aged. Sweat Gland Neoplasms / diagnosis. Sweat Gland Neoplasms / drug therapy. Sweat Gland Neoplasms / surgery

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19486582.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Dünne AA, Kuropkat C, Sapundzhiev N, Ramaswamy A, Sesterhenn A, Schulz S, Werner JA: Intravenous chemotherapy with cisplatin for regional lymph node metastases of auricular VX2 carcinoma. Anticancer Res; 2004 May-Jun;24(3a):1785-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravenous chemotherapy with cisplatin for regional lymph node metastases of auricular VX2 carcinoma.
  • INTRODUCTION: The VX2 carcinoma is well established as a useful model for studies on treatment of primary tumors of various locations including the rabbit's auricle; however, limited experience exists on the treatment modalities of lymph node (LN) metastases.
  • In this investigation we studied the frequency and extent of lymphogenic metastatic spread of auricular VX2-carcinomas and their response to systemic chemotherapy.
  • MATERIALS AND METHODS: Induction of a right-sided auricular VX2-carcinoma in 17 healthy New Zealand white rabbits was followed by ablation of the right auricle and intravenous application of 1 mg/kg KG CDDP (cisdiamminedichloroplatinum (II)) dissolved in 2 ml NaCl via the left-sided auricular vein in 10 rabbits (group 1), while 7 rabbits (group 2) remained untreated.
  • Following intravenous cisplatin therapy (ICT), 6/10 animals showed no vital tumor cells within LN metastases of the first draining LN station, while 4/10 animals had necrotic LN metastases limited to the parotideal LN. Group 2.
  • CONCLUSION: The auricular VX2-carcinoma, characterized by frequent lymphogenic metastatic spread and response of LN metastases to ICT, offers an excellent animal model for further studies on the optimised treatment of lymphogenic metastatic spread in HNSCC.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cisplatin / pharmacology. Ear Neoplasms / drug therapy
  • [MeSH-minor] Animals. Ear, External / blood supply. Female. Infusions, Intravenous. Lymphatic Metastasis. Rabbits

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15274356.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Mangin L, Tremel F, Cracowski JL, Chavanon O, Mallion JM, Baguet JP: [Pulmonary embolism with right intra-auricular thrombus. Fatal outcome during fibrinolysis]. Presse Med; 2002 Sep 28;31(31):1454-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary embolism with right intra-auricular thrombus. Fatal outcome during fibrinolysis].
  • INTRODUCTION: The spontaneous prognosis of pulmonary embolism associated with mobile intra-cardiac thrombus is most severe, and the choice of a therapeutic strategy is often difficult.
  • OBSERVATION: The treatment of a patient with intravenous fibrinolytics for massive pulmonary embolism and right atrium thrombus was complicated by his early death.
  • COMMENTS: In this pathology, several therapeutic approaches are possible.
  • Heparin treatment alone has been proposed as an alternative when the other two techniques are contraindicated.
  • These techniques currently require assessment in a randomized study, in order to define the appropriate therapeutic strategy.
  • [MeSH-major] Heart Atria. Pulmonary Embolism / drug therapy. Thrombolytic Therapy / adverse effects. Thrombosis / drug therapy
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Fatal Outcome. Humans. Lung / pathology. Lung Neoplasms / pathology. Lymphatic Metastasis. Male. Pulmonary Artery / pathology. Risk Factors. Venous Thrombosis / diagnosis. Venous Thrombosis / drug therapy. Venous Thrombosis / pathology

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12395736.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Devaney KO, Boschman CR, Willard SC, Ferlito A, Rinaldo A: Tumours of the external ear and temporal bone. Lancet Oncol; 2005 Jun;6(6):411-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumours of the external ear and temporal bone.
  • Less commonly, auricular signs and symptoms are the result of non-neoplastic and neoplastic space-occupying lesions.
  • The external ear can be the site of development of squamous carcinomas and basal-cell carcinomas; the middle ear and inner ear can host metastatic deposits, and primary squamous carcinomas and adenocarcinomas.
  • Most auricular malignant diseases occur in adulthood; only the rhabdomyosarcomas of the middle ear arise in children.
  • Most malignant diseases of the auricular apparatus are treated by a combination of surgery (commonly including radical excision of temporal bone), radiotherapy, and chemotherapy.
  • [MeSH-major] Ear Neoplasms / diagnosis. Ear Neoplasms / therapy. Ear, External. Skull Neoplasms / diagnosis. Skull Neoplasms / therapy. Temporal Bone
  • [MeSH-minor] Combined Modality Therapy. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925819.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 76
  •  go-up   go-down


10. Ling R, Li Y, Yao Q, Chen T, Zhu D, Jun Y, Chen J: Lymphatic chemotherapy induces apoptosis in lymph node metastases in a rabbit breast carcinoma model. J Drug Target; 2005 Feb;13(2):137-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic chemotherapy induces apoptosis in lymph node metastases in a rabbit breast carcinoma model.
  • The purpose of the study was to evaluate the potential of lymphatic chemotherapy in inducing apoptosis in axillary lymph node metastases in a rabbit breast cancer model.
  • Treatment was carried out once axillary lymph node reached 5 mm in the maximum diameter.
  • Group B received free adriamycin (FADR) administered into the auricular vein.
  • Group C received a sham treatment.
  • Treatment was repeated every 48 h.
  • Axillary lymph nodes were dissected out 48 h after the third treatment.
  • The nodal sizes before and after the treatment were measured.
  • The therapeutic effect was evaluated in terms of the node volume ratio and apoptotic index (AI) of metastatic cells in nodes identified with TUNEL technique.
  • These data suggest that lymphatic chemotherapy appears to be a promising method to induce apoptosis in lymph node metastases
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Apoptosis / drug effects. Carcinoma / drug therapy. Doxorubicin / therapeutic use. Lymph Nodes / drug effects. Mammary Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Female. In Situ Nick-End Labeling. Injections, Intravenous. Liposomes. Lymphatic Metastasis. Neoplasm Transplantation. Rabbits

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823965.001).
  • [ISSN] 1061-186X
  • [Journal-full-title] Journal of drug targeting
  • [ISO-abbreviation] J Drug Target
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 80168379AG / Doxorubicin
  •  go-up   go-down


11. Harding C, Harris A, Chadwick D: Auricular acupuncture: a novel treatment for vasomotor symptoms associated with luteinizing-hormone releasing hormone agonist treatment for prostate cancer. BJU Int; 2009 Jan;103(2):186-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Auricular acupuncture: a novel treatment for vasomotor symptoms associated with luteinizing-hormone releasing hormone agonist treatment for prostate cancer.
  • OBJECTIVES: To evaluate the role of auricular acupuncture (AA) in men receiving luteinizing-hormone releasing hormone (LHRH) analogues for carcinoma of the prostate, as vasomotor symptoms can affect the quality of life in such men, and similar symptoms in postmenopausal women have been successfully treated with AA.
  • PATIENTS AND METHODS: In all, 60 consecutive patients with prostate cancer and on LHRH agonist treatment (median age 74 years, range 58-83) consented to weekly AA for 10 weeks.
  • The validated 'Measure Yourself Concerns and Well-Being' questionnaire (a six-point scale to assess symptom severity) was used to assess concerns and well-being before and after treatment.
  • RESULTS: All men completed the treatment with no adverse events recorded, apart from transient exacerbation of symptoms in two men; 95% of patients reported a decrease in the severity of symptoms, from a mean 5.0 to 2.1 (Student's t-test, P < 0.01).
  • CONCLUSIONS: The symptomatic improvement was at levels comparable with that from pharmacotherapy, and cost analysis showed AA to be a viable alternative.
  • Larger randomized studies are needed to fully evaluate AA against more conventional treatments, and these are planned.
  • [MeSH-major] Acupuncture, Ear / methods. Androgen Antagonists / adverse effects. Gonadotropin-Releasing Hormone / agonists. Hot Flashes / therapy. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Male. Middle Aged. Pilot Projects. Quality of Life. Surveys and Questionnaires. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18710455.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Antagonists; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


12. Peng H, Peng HD, Xu L, Lao LX: [Efficacy of acupuncture in treatment of cancer pain: a systematic review]. Zhong Xi Yi Jie He Xue Bao; 2010 Jun;8(6):501-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of acupuncture in treatment of cancer pain: a systematic review].
  • BACKGROUND: Although acupuncture is a well-established treatment for cancer pain and its effects have been widely reported in recent two decades, there is still controversy over whether its efficacy is better than placebo.
  • OBJECTIVE: To evaluate the efficacy of acupuncture therapy on cancer pain.
  • INCLUSION CRITERIA: All randomized controlled trials (RCTs) comparing acupuncture therapy with placebo, Western drugs, Chinese herbal medicines, or comparing acupuncture therapy plus drug treatment with drug treatment.
  • The high-quality trial showed that auricular acupuncture therapy was significantly superior to placebo in pain alleviation.
  • The other six low-quality trials with non-placebo showed that acupuncture therapy had some positive effects.
  • [MeSH-major] Acupuncture Therapy. Neoplasms / complications. Pain / etiology. Pain Management / methods
  • [MeSH-minor] Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acupuncture.
  • MedlinePlus Health Information. consumer health - Pain.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20550871.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


13. Aygenç E, Dakak Y, Ozdem C: [A case of auricular malignant melanoma]. Kulak Burun Bogaz Ihtis Derg; 2002 Jan-Feb;9(1):63-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of auricular malignant melanoma].
  • We performed auricular excision, total parathyroidectomy, and extended radical neck dissection in a 36-year-old male patient who developed auricular malignant melanoma.
  • The patient received radiotherapy and chemotherapy after surgery.
  • [MeSH-major] Ear Neoplasms / surgery. Melanoma / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Diagnosis, Differential. Ear, External / surgery. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Neck Dissection. Parathyroidectomy. Radiotherapy, Adjuvant. Reconstructive Surgical Procedures. Skin Transplantation

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12122628.001).
  • [ISSN] 1300-7475
  • [Journal-full-title] Kulak burun boğaz ihtisas dergisi : KBB = Journal of ear, nose, and throat
  • [ISO-abbreviation] Kulak Burun Bogaz Ihtis Derg
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


14. Takagi S, Inenaga R, Oya R, Nakamura S, Ikemura K: Blood vessel density correlates with the effects of targeted intra-arterial carboplatin infusion with concurrent radiotherapy for squamous cell carcinomas of the oral cavity and oropharynx. Br J Cancer; 2006 Jun 5;94(11):1580-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the i.a. group, carboplatin was infused into the lingual artery, and in the intravenous (i.v.) group, carboplatin was infused through the auricular vein.
  • In the clinical study, we evaluated 19 patients with squamous cell carcinomas of the oral cavity and oropharynx, who had undergone targeted carboplatin i.a. chemoradiotherapy and had been administered i.a. tegafur/uracil chemotherapy before surgery.
  • In the clinical study, using multivariate logistic regression analysis, only the BVD was related independently to the treatment effect.
  • Therefore, BVD is a valid predictor of the effects of i.a. targeted carboplatin chemotherapy and concurrent radiotherapy for treating human oral and oropharyngeal squamous cell carcinomas.
  • [MeSH-major] Blood Vessels / pathology. Carboplatin / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Mouth Neoplasms / pathology. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Aug 15;92(4):903-8 [11550164.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2474-84 [9059336.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jan;33(1):2-7 [14690652.001]
  • [Cites] Laryngoscope. 2004 Mar;114(3):411-7 [15091211.001]
  • [Cites] Br J Cancer. 2004 Jun 1;90(11):2062-6 [15150563.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4491-5 [3731104.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Nov;12(11):2047-50 [3771322.001]
  • [Cites] Science. 1987 Jan 23;235(4787):442-7 [2432664.001]
  • [Cites] Scand J Dent Res. 1987 Jun;95(3):229-49 [3299675.001]
  • [Cites] Lancet. 1987 Jun 20;1(8547):1398-402 [2884496.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):545-53 [10974475.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6449-65 [2684393.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1619-25 [2311071.001]
  • [Cites] Radiother Oncol. 1991;20 Suppl 1:35-40 [2020767.001]
  • [Cites] Lancet. 1992 Jul 18;340(8812):145-6 [1378165.001]
  • [Cites] Lancet. 1992 Nov 7;340(8828):1120-4 [1279332.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Jun;119(6):612-7 [8499090.001]
  • [Cites] Am J Surg. 1997 Nov;174(5):561-4 [9374238.001]
  • [Cites] Laryngoscope. 2002 Oct;112(10):1742-9 [12368607.001]
  • (PMID = 16670721.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ PMC2361327
  •  go-up   go-down


15. Sima L, Wang X: [Therapeutic effect of acupuncture on cisplatin-induced nausea and vomiting]. Zhongguo Zhen Jiu; 2009 Jan;29(1):3-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic effect of acupuncture on cisplatin-induced nausea and vomiting].
  • OBJECTIVE: To observe therapeutic effect of acupuncture combined with antiemetic on cisplatin-induced nausea and vomiting.
  • METHODS: By using paired, cross-controlled trial design, 66 cases of chemotherapy were divided into group A and B, 33 cases in each group.
  • For the group A, chemotherapy, tropisetron and acupuncture therapy were adopted in the first chemotherapy cycle and the same chemotherapy program, tropisetron and sham acupuncture were used in the next cycle.
  • For the group B, chemotherapy, tropisetron and sham acupuncture were given in the first chemotherapy cycle and the same chemotherapy program, tropisetron and acupuncture therapy were applied in the next cycle.
  • Zusanli (ST 36), Neiguan (PC 6) and Gongsun (SP 4) and auricular point Wei (stomach) were selected for acupuncture therapy, and the points at 3 cm lateral to Zusanli (ST 36) , Neiguan (PC 6) and Gongaun (SP 4) and auricular point corresponding to scapha level were selected for sham acupuncture.
  • Acupuncture treatment or sham-acupuncture was given for 6 consecutive days, once each day and antiemetic tropisetron 5 mg was given to the two groups as basic antiemetic prophylaxis for 6 days, once daily.
  • The therapeutic effects on nausea and vomiting in the 6 days were compared between the acupuncture group and the sham-acupuncture group in the two chemotherapeutic cycles.
  • RESULTS: The effective rates for nausea in the 2nd day and the 4th day were 87.1% and 79.0% in acupuncture group, which were superior to 59.4% and 57.8% in the sham-acupuncture group, respectively (both P < 0.05); and the therapeutic effects on vomiting in the 3rd-6th day in the acupuncture group were better than those in the sham-acupuncture group (P < 0.05).
  • [MeSH-major] Acupuncture Therapy. Cisplatin / adverse effects. Nausea / therapy. Vomiting / therapy
  • [MeSH-minor] Acupuncture Points. Adolescent. Adult. Aged. Antiemetics / administration & dosage. Breast Neoplasms / complications. Breast Neoplasms / drug therapy. Female. Humans. Lung Neoplasms / complications. Lung Neoplasms / drug therapy. Male. Middle Aged

  • Genetic Alliance. consumer health - Nausea.
  • Genetic Alliance. consumer health - Vomiting.
  • MedlinePlus Health Information. consumer health - Acupuncture.
  • MedlinePlus Health Information. consumer health - Nausea and Vomiting.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19186712.001).
  • [ISSN] 0255-2930
  • [Journal-full-title] Zhongguo zhen jiu = Chinese acupuncture & moxibustion
  • [ISO-abbreviation] Zhongguo Zhen Jiu
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antiemetics; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Mansky PJ, Wallerstedt DB: Complementary medicine in palliative care and cancer symptom management. Cancer J; 2006 Sep-Oct;12(5):425-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most cancer patients use CAM with the hope of boosting the immune system, relieving pain, and controlling side effects related to disease or treatment.
  • Only a minority of patients include CAM in the treatment plan with curative intent.
  • In the area of cancer symptom management, auricular acupuncture, therapeutic touch, and hypnosis may help to manage cancer pain.
  • Music therapy, massage, and hypnosis may have an effect on anxiety, and both acupuncture and massage may have a therapeutic role in cancer fatigue.
  • Acupuncture and selected botanicals may reduce chemotherapy-induced nausea and emesis, and hypnosis and guided imagery may be beneficial in anticipatory nausea and vomiting.
  • Most CAM approaches to the treatment of cancer are safe when used by a CAM practitioner experienced in the treatment of cancer patients.
  • The potential for many commonly used botanical to interact with prescription drugs continues to be a concern.
  • [MeSH-major] Complementary Therapies / utilization. Neoplasms / therapy. Palliative Care
  • [MeSH-minor] Humans. Pain, Intractable / therapy


17. Rinaldo A, Devaney KO, Ferlito A: Merkel cell carcinoma of the auricle. Acta Otolaryngol; 2005 Feb;125(2):125-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma of the auricle.
  • Merkel cell carcinoma (MCC) is an uncommon cutaneous neoplasm which arises in adults with a peak incidence in the sixth and seventh decades.
  • Among head and neck primary sites, auricular MCC has proven to be rare and only 20 cases have been reported in the literature.
  • Auricular MCC follows the same aggressive course as has been documented for MCC arising elsewhere: the tumor has a propensity for recurring locally and metastasizing to regional lymph nodes and distant sites.
  • Location of MCC in the auricular regions does not appear to confer any survival advantage compared with MCC arising elsewhere.
  • The mainstay of treatment is surgery, with attempts at complete surgical excision being of paramount importance.
  • What role regional node dissection, radiation therapy and chemotherapy may play in the standard treatment of auricular MCC remains to be clearly established.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Ear, External. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / radiotherapy. Head and Neck Neoplasms / surgery. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880940.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 34
  •  go-up   go-down


18. Alimi D, Rubino C, Pichard-Léandri E, Fermand-Brulé S, Dubreuil-Lemaire ML, Hill C: Analgesic effect of auricular acupuncture for cancer pain: a randomized, blinded, controlled trial. J Clin Oncol; 2003 Nov 15;21(22):4120-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analgesic effect of auricular acupuncture for cancer pain: a randomized, blinded, controlled trial.
  • PURPOSE: During the last 30 years, auricular acupuncture has been used as complementary treatment of cancer pain when analgesic drugs do not suffice.
  • The purpose of this study is to examine the efficacy of auricular acupuncture in decreasing pain intensity in cancer patients.
  • PATIENTS AND METHODS: Ninety patients were randomly divided in three groups; one group received two courses of auricular acupuncture at points where an electrodermal signal had been detected, and two placebo groups received auricular acupuncture at points with no electrodermal signal (placebo points) and one with auricular seeds fixed at placebo points.
  • Patients had to be in pain, attaining a visual analog score (VAS) of 30 mm or more after having received analgesic treatment adapted to both intensity and type of pain, for at least 1 month of therapy.
  • Treatment efficacy was based on the absolute decrease in pain intensity measured 2 months after randomization using the VAS.
  • RESULTS: The main outcome was pain assessed at 2 months, with the assessment at 1 month carried over to 2 months for the eight patients who interrupted treatment after 1 month.
  • CONCLUSION: The observed reduction in pain intensity measured on the VAS represents a clear benefit from auricular acupuncture for these cancer patients who are in pain, despite stable analgesic treatment.
  • [MeSH-major] Acupuncture, Ear. Ear / physiopathology. Electroacupuncture. Pain Management
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analgesics / therapeutic use. Antineoplastic Agents / adverse effects. Chronic Disease. Female. Humans. Male. Middle Aged. Neoplasms / drug therapy. Neoplasms / pathology. Pain / etiology. Pain / physiopathology. Pain Measurement. Placebos. Sensory Thresholds. Single-Blind Method

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14615440.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics; 0 / Antineoplastic Agents; 0 / Placebos
  •  go-up   go-down


19. Greene AK, Rogers GF, Mulliken JB: Management of parotid hemangioma in 100 children. Plast Reconstr Surg; 2004 Jan;113(1):53-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most problematic infantile hemangiomas are successfully treated with pharmacological therapy.
  • The indications for and response to treatment and the need for surgical procedures were documented and statistically analyzed.
  • Eighty-eight percent involved nearby structures (ear, 70 percent; lip, 34 percent; subglottic region, 21 percent; eye, 18 percent; and nose, 3 percent).
  • Seventy infants received pharmacological treatment.
  • Twenty-one patients received interferon: 11 in whom corticosteroid therapy had failed, seven in whom the tumor stabilized with corticosteroid therapy but further regression was needed, and three who had interferon as primary therapy.
  • The overall response rate to pharmacological therapy was 98 percent.
  • A reconstructive procedure was necessary during the involuting or involuted phase in 66 percent of patients: 92 percent had preauricular excision of redundant skin and/or fibrofatty tissue and 37 percent of patients had auricular revision.
  • In summary, drug therapy was effective in the majority of infants with parotid hemangioma, whether given because the tumor was large, deforming, ulcerated, or involved nearby structures with functional consequences.
  • Infantile hemangioma in the parotid gland responded to pharmacological treatment in a similar manner as hemangioma in other locations.
  • [MeSH-major] Hemangioma / therapy. Parotid Neoplasms / therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Child. Child, Preschool. Female. Humans. Infant. Interferon-alpha / therapeutic use. Male. Retrospective Studies. Skin Neoplasms / congenital. Skin Neoplasms / pathology. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14707622.001).
  • [ISSN] 0032-1052
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Interferon-alpha
  •  go-up   go-down


20. Rozin AP, Gez E, Bergman R: Recurrent auricular chondritis and cartilage repair. Ann Rheum Dis; 2005 May;64(5):783-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent auricular chondritis and cartilage repair.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Buserelin / adverse effects. Ear Deformities, Acquired / chemically induced. Polychondritis, Relapsing / chemically induced
  • [MeSH-minor] Adenocarcinoma / drug therapy. Aged. Ear Cartilage. Humans. Male. Prostatic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15834060.001).
  • [ISSN] 0003-4967
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; PXW8U3YXDV / Buserelin
  • [Other-IDs] NLM/ PMC1755473
  •  go-up   go-down






Advertisement